We compared the effects of bone marrow-derived mononuclear cells (BMMCs) and mesenchymal stromal cells (MSCs) on airway inflammation and remodeling and lung mechanics in experimental allergic asthma. C57BL/6 mice were sensitized and challenged with ovalbumin (OVA group). A control group received saline using the same protocol. Twenty-four hours after the last challenge, groups were further randomized into subgroups to receive saline, BMMCs (2 × 10 6 ) or MSCs (1 × 10 5 ) intratracheally. BMMC and MSC administration decreased cell infiltration, bronchoconstriction index, alveolar collapse, collagen fiber content in the alveolar septa, and interleukin (IL)-4, IL-13, transforming growth factor (TGF)-␤ and vascular endothelial growth factor (VEGF) levels compared to OVA-SAL. Lung function, alveolar collapse, collagen fiber deposition in alveolar septa, and levels of TGF-␤ and VEGF improved more after BMMC than MSC therapy. In conclusion, intratracheal BMMC and MSC administration effectively modulated inflammation and fibrogenesis in an experimental model of asthma, but BMMCs was associated with greater benefit in terms of reducing levels of fibrogenesis-related growth factors.
Introduction
Asthma is a chronic inflammatory disease of the airways (Murphy and O'Byrne, 2010) associated with structural changes such as subepithelial fibrosis, mucous metaplasia, wall thickening, smooth muscle cell hypertrophy and hyperplasia, myofibroblast hyperplasia, vascular proliferation, and extracellular matrix abnormalities . These changes accelerate decline in lung function despite treatment with inhaled corticosteroids. Therefore, new strategies that can hasten the repair process and attenuate airway inflammation and remodeling are warranted.
Several recent studies have investigated the impact of bone marrow-derived mononuclear cells (BMMCs) (Abreu et al., 2011) or mesenchymal stromal cells (MSCs) (Firinci et al., 2011; Goodwin et al., 2011; Ou-Yang et al., 2011; Kapoor et al., 2012) in experimental allergic asthma. Each has specific advantages. BMMCs can be used in autologous transplantation, on the same day of harvesting, and avoid common complications such as graft-versus-host disease, whereas MSCs exhibit multilineage differentiation potential and immune-privileged features and enable allogenic use (Mathieu et al., 2009; Lu et al., 2011) . So far, however, no study has evaluated the effects of cell type in cell therapy of experimental asthma. Furthermore, most cell therapies have been studied at the onset of the remodeling process; there are no data on the effects of cell therapy once the remodeling process of asthma is already established. Within this context, the present study sought to investigate and compare the therapeutic effects of BMMCs or MSCs on lung mechanics and histology, collagen fiber content in the airway and alveolar septa, and levels of cytokines and growth factors in lung tissue in a murine model of experimental allergic asthma.
Materials and methods
This study was approved by the Ethics Committee of the Health Sciences Center, Federal University of Rio de Janeiro.
Extraction and characterization of BMMCs and MSCs
BMMCs and MSCs were obtained from male C57BL/6 mice (weight 20-25 g, n = 5 per group) and administered on the day of collection or after 3 passages, respectively. Bone marrow cells were aspirated from the femur and tibia by flushing the bone marrow cavity with Dulbecco's modified Eagle's medium (DMEM) (Life Technologies, Grand Island, NY, USA). After a homogeneous cell suspension was achieved, cells were centrifuged (400 × g for 10 min), plated in DMEM containing 20% fetal bovine serum (MSCs) or re-suspended in DMEM (BMMCs) and added to FicollHypaque (Histopaque 1083, Sigma Chemical Co., St. Louis, MO, USA), and again centrifuged and supplemented with phosphatebuffered saline (PBS). Cell characterization was performed by flow cytometry using antibodies against CD45 (leukocytes), CD34 (hematopoietic precursors), CD3, CD8, and CD4 (T lymphocytes), CD19 (B lymphocytes), CD14 (monocytes), and CD11b, CD29 and CD45 (non-hematopoietic precursors) (BD Biosciences, USA). The absence of CD34 and CD45 and the presence of CD14, CD29, and Sca-1 were used to identify MSCs. Furthermore, MSCs were identified by the capacity to differentiate into osteoblasts and chondroblasts.
Animal preparation and experimental protocol
Thirty-six female C57BL/6 mice (weight, 20-25 g) were randomly assigned to two groups. In the OVA group, mice were immunized using an adjuvant-free protocol by intraperitoneal injection of sterile ovalbumin (OVA, 10 g OVA in 100 l saline) on 7 alternate days. Forty days after the start of sensitization, 20 g of OVA in 20 l of saline were instilled intratracheally. This procedure was performed 3 times at 3-day intervals (Xisto et al., 2005) . The control group (C) received saline using the same protocol. The C and OVA groups were further randomized to receive saline solution (0.9% NaCl, 50 l, SAL), BMMCs (2 × 10 6 in 50 l) or MSCs (1 × 10 5 in 50 l) intratracheally, 24 h after the last challenge (Fig. 1) . For the administration of saline, BMMCs or MSCs, mice were anesthetized with sevoflurane, the trachea of each mouse was dissected, and cells were slowly injected. Furthermore, small aliquots were used for immunophenotypic flow cytometry characterization of the injected cell populations and to evaluate the ability of MSCs to differentiate into osteoblasts and chondroblasts (Fig. 2) .
Mechanical parameters
One week after cell therapy, the animals were sedated (diazepam 1 mg i.p.), anesthetized (thiopental sodium 20 mg/kg i.p.), tracheotomized, paralyzed (vecuronium bromide, 0.005 mg/kg i.v.), and ventilated with a constant flow ventilator (Samay VR15; Universidad de la Republica, Montevideo, Uruguay) set to the following parameters: frequency 100 breaths/min, tidal volume (V T ) 0.2 mL, and fraction of inspired oxygen (FiO 2 ) 0.21. The anterior chest wall was surgically removed and a positive end-expiratory pressure of 2 cm H 2 O applied. Airflow and tracheal pressure (Ptr) were measured. Lung mechanics were analyzed by the end-inflation occlusion method. In an open chest preparation, Ptr reflects transpulmonary pressure (PL). Briefly, after end-inspiratory occlusion, there is a rapid initial decline in PL ( P 1 ,L) from the preocclusion value down to an inflection point (Pi), followed by a slow pressure decay ( P 2 ,L), until a plateau is reached. This plateau corresponds to the elastic recoil pressure of the lung (Pel). P 1 ,L selectively reflects the pressure used to overcome airway resistance. P 2 ,L reproduces the pressure spent by stress relaxation, or the viscoelastic properties of the lung, as well as a small contribution of pendelluft. Static lung elastance (Est,L) was determined by dividing Pel by V T . Lung mechanics measurements were obtained 10 times in each animal. All data were analyzed using ANADAT software (RHT-InfoData, Inc., Montreal, Quebec, Canada). All experiments lasted less than 15 min.
Lung histology
Laparotomy was performed immediately after determination of lung mechanics. Heparin (1000 IU) was injected into the vena cava. The trachea was clamped at end-expiration, and the abdominal aorta and vena cava were sectioned, producing massive hemorrhage and terminal bleeding for euthanasia. The right lung was then removed, fixed in 3% buffered formalin and embedded in paraffin; 4-m-thick slices were cut and stained with hematoxylin-eosin.
Lung histology analysis was performed with an integrating eyepiece with a coherent system consisting of a grid with 100 points and 50 lines (known length) coupled to a conventional light microscope (Olympus BX51, Olympus Latin America-Inc., Values expressed as median (interquartile range) of 6 animals per group. All values were computed in 10 random, non-coincident fields per mouse. Fractional area of normal and collapsed alveoli, mononuclear (MN) and polymorphonuclear (PMN) cells, and contraction index. Experimental groups: C, mice sensitized and challenged with saline; OVA, mice sensitized and challenged with ovalbumin; SAL, mice given saline; BMMC, mice treated with BMMC 24 h after the last challenge (2 × 10 6 ); MSC, mice treated with MSC 24 h after the last challenge (1 × 10 5 ). * Significantly different from C-SAL (p < 0.05). ** Significantly different from OVA-SAL (p < 0.05). # Significantly different from OVA-BMMC (p < 0.05).
Fig. 4.
Representative photomicrographs of lung parenchyma (upper panels) and airways (lower panels), hematoxylin-eosin stain. Collapsed areas in the lung parenchyma and a reduction in central airway diameter, as well as increased cell infiltration, are visible in the OVA-SAL animals. Experimental groups: C, mice sensitized and challenged with saline; OVA, mice sensitized and challenged with ovalbumin; SAL, mice given saline; BMMC, mice treated with BMMC 24 h after the last challenge (2 × 10 6 ); MSC, mice treated with MSC 24 h after the last challenge (1 × 10 5 ). Original magnification: 200× and 400× (upper and lower panels, respectively). Bars = 100 m. Brazil). The volume fraction of collapsed and normal pulmonary areas, the magnitude of bronchoconstriction (contraction index), and the number of mononuclear and polymorphonuclear cells in pulmonary tissue were determined by the point-counting technique across 10 random, non-coincident microscopic fields (Weibel, 1990; Hsia et al., 2010) . Collagen was quantified in the airways and alveolar septa by the Picrosirius polarization method, using Image-Pro Plus 6.0 software (Xisto et al., 2005; Antunes et al., 2009 Antunes et al., , 2010 .
Enzyme-linked immunosorbent assay (ELISA)
Levels of interleukin (IL)-4, IL-13, transforming growth factor (TGF)-␤ and vascular endothelial growth factor (VEGF) in lung tissue were evaluated by ELISA using matched antibody pairs from PrepoTech and R&D Systems (Minneapolis, MN, USA), according to manufacturer instructions. Results are expressed as pg/mL.
Statistical analysis
One-way ANOVA on ranks followed by Dunn's test was used for comparison of between-group differences. Data were expressed as medians and interquartile ranges. All tests were performed using the SigmaStat 3.1 software package (Jandel Corporation, San Rafael, CA, USA), and statistical significance was established as p < 0.05.
Results
The following subpopulations were identified in the pool of injected BMMCs: total lymphocytes (lower SSC, CD45+/CD11+/CD29−/CD34− = 19.6%), T lymphocytes (lower SSC/ CD45+/CD3+/CD34− = 5.4%), T helper lymphocytes (CD3+/CD4+/ CD8− = 1.98%), cytotoxic T lymphocytes (CD3+/CD4−/CD8+ = 5.06%), monocytes (CD45+/CD29+/CD11b+ low/CD34−/CD3− = 7.24%), hematopoietic progenitors (CD34+/CD45+ = 2.65%), and possible MSCs (CD45−/CD34−/CD11b− = 3.8%). Similarly, MSCs were characterized as CD45−/CD14−/CD34−/CD29+/Sca1+ and were capable of differentiation into osteoblasts and chondroblasts (Fig. 2) . The number of MSCs administered was similar to that present in the pool of BMMCs.
According to lung function analysis, the OVA-SAL groups exhibited higher Est,L (57%), P1,L (76%), and P2,L (53%) as compared with the C-SAL group. Both cell therapies were effective for reduction of P1,L and P2,L. However, these decrements were more pronounced after BMMC therapy than MSC therapy. Furthermore, only BMMC therapy was associated with a significant decrease in Est,L (Fig. 3) .
Lung morphometric examination demonstrated a significant increase in fractional area of alveolar collapse, contraction index, number of mononuclear and polymorphonuclear cells, and collagen fiber content in the airways and alveolar septa in the OVA-SAL group compared to the C-SAL group (Table 1 and Figs. 4 and 5). Both cell therapies minimized the fractional area of alveolar collapse and polymorphonuclear cell infiltration in lung tissue (Table 1 and Fig. 4) , and completely reversed changes in the contraction index (Table 1 ) and airway wall thickness (Fig. 4) . Furthermore, both therapies decreased the amount of collagen fiber, specifically in the alveolar septa. BMMC therapy led to a more significant reduction in alveolar collapse and collagen fiber deposition in alveolar septa as compared with MSC therapy (Table 1 and Figs. 5 and 6). No significant difference was observed in the amount of collagen fiber in the airways after both therapies (Figs. 5 and 6 ).
Levels of IL-4, IL-13, TGF-␤ and VEGF in lung tissue were higher in the OVA-SAL group than in the C-SAL group. BMMC and MSC administration yielded similar reductions in IL-4 and IL-13, whereas TGF-␤ and VEGF levels presented a greater reduction after BMMC therapy than after MSC therapy (Fig. 7) .
Discussion
In the murine model of allergic asthma used herein, BMMC and MSC administration yielded similar beneficial effects on airway inflammation, as shown by significant reductions in the number of mononuclear and polymorphonuclear cells and in the levels of pro-inflammatory cytokines (IL-4 and IL-13) in lung tissue. However, BMMC administration led to greater improvement in lung mechanics and a greater reduction in fractional area of alveolar collapse, collagen fiber content in the alveolar septa, and growth factor levels (TGF-␤ and VEGF) as compared with MSCs. Our findings suggest that both cell types play an important role in the inflammatory process in experimental allergic asthma, but suggest that BMMCs are more effective than MSCs at reducing the remodeling process.
Several studies have investigated the effects of BMMC (Abreu et al., 2011) and MSC (Goodwin et al., 2011; Ou-Yang et al., 2011; Kapoor et al., 2012) administration in experimental asthma. We have previously demonstrated that pre-treatment with BMMCs curtails airway inflammation and remodeling and induces lung repair, thus improving lung mechanics (Abreu et al., 2011) . The rationale supporting BMMC therapy relies on the knowledge that the functional effects of these cells result from a balance between different cell types, with involvement of all cells with the potential to yield beneficial effects (Mathieu et al., 2009; Araujo et al., 2010; Lu et al., 2011; Cruz et al., 2012) . This hypothesis is supported by the crosstalk between multiple cell types that occurs during embryonic development (Rafii and Lyden, 2003) . Additionally, BMMCs can be administered easily and safely, on the day of harvesting, at lower costs, and without risk of cell rejection (graft-versus-host disease). MSCs also lead to beneficial effects in experimental asthma when administered during sensitization or before challenge (Firinci et al., 2011; Goodwin et al., 2011; Lee et al., 2011) . MSCs exhibit multilineage differentiation potential (Jiang et al., 2002) , support adequate tissue repair, have immune-privileged features and can be used in allogeneic therapy.
No previous study has compared the effects of BMMCs and MSCs in experimental asthma, particularly once the remodeling process is already established. For this purpose, we employed a C57BL/6 mouse model of allergic asthma (Abreu et al., 2011) , which features eosinophilia and Th2 pro-inflammatory cytokines (Yu et al., 2006; Allen et al., 2012) . Even though early therapy with BMMCs modulates lung inflammation and remodeling regardless of the route of administration , in the present study, both cell types were instilled intratracheally, since a more direct administration route will ensure delivery of a higher number of cells to the airway and alveoli (Bonios et al., 2011) . To ascertain whether the effects of BMMC therapy resulted from the balance between cell types rather than strictly from the presence of MSCs in the bone marrow pool, approximately the same number of MSCs found in the bone marrow mononuclear fraction according to flow cytometry was administered to the OVA-MSC group (4% MSCs in 2 × 10 6 BMMCs, approximately 1 × 10 5 MSCs).
Asthma is an inflammatory disease classically associated with increased expression of T helper 2 (Th2) cytokines, mainly IL-4 and IL-13. Among other functions, these cytokines induce Th2 differentiation bias, fibroblast proliferation, extracellular matrix deposition, airway hyperresponsiveness, epithelial cell apoptosis, mucus production, and eosinophil recruitment (Hamid and Tulic, 2009 ). Therefore, they play important roles not only in the inflammatory process, but also in airway remodeling, and are thus considered important therapeutic targets (Borowski et al., 2008; Bellini et al., 2011) . In this context, both BMMC and MSC cell therapies were found to reduce IL-4 and IL-13 levels, possibly as a result of the decrease in eosinophil infiltration and collagen fiber content in alveolar septa. Interestingly, these cells were unable to reduce airway fibrosis, which may be explained by the onset of the collagen deposition process before initiation of cell therapy, unlike previous studies in which cells were administrated as pretreatment and, therefore, before the ultrastructural changes characteristic of the remodeling process had occurred (Abreu et al., 2011; Goodwin et al., 2011) . Further studies are recommended to assess whether long-term treatment and the administration of repeated doses of either cell type could further reduce collagen fiber content in the airways.
Both BMMC and MSC administration were effective in minimizing lung remodeling in the present model of allergic asthma. However, BMMCs promoted a more marked reduction of TGF-␤ and VEGF levels than MSCs. TGF-␤ is a profibrotic agent, produced by epithelium, fibroblasts and inflammatory cells (mainly eosinophils) (Minshall et al., 1997; Lee et al., 2001) . It is capable of inducing epithelial detachment, epithelial-mesenchymal transition, subepithelial fibrosis, and airway smooth muscle hyperplasia and migration, and plays an important role in airway remodeling (Halwani et al., 2011) . The reduction in TGF-␤ observed in the present study was consistent with a previous report (Abreu et al., 2011) , while another study associated the beneficial effects of MSC therapy with stimulation of TGF-␤ expression (Nemeth et al., 2010) . TGF-␤ also contributes to the increased vascularity of asthmatic airways through induction of VEGF, a key angiogenic molecule (Willems-Widyastuti et al., 2011) that plays a prominent role in the remodeling process in experimental asthma (Lee et al., 2006) . VEGF levels also declined after BMMC and MSC therapy, in close correlation with the changes observed in TGF-␤ levels. Therefore, it seems that BMMC and, less efficiently, MSC administration modulate steps in the airway remodeling pathway involving IL-4, IL-13, eosinophils, TGF-␤, and VEGF.
Although the pathologic characteristics of asthma are well known, the association between these features and physiological impairment is less clear. Furthermore, it is noteworthy that not only central airways, but also distal airways and lung parenchyma, are involved in the functional changes of asthma (Xisto et al., 2005) . In the experimental model of allergic asthma used herein, we observed histological changes such as increased alveolar collapse and contraction index, which were due to alterations in airway wall thickness and collagen fiber deposition. These morphological changes led to increased lung static elastance and viscoelastic and resistive pressures respectively. Both cell therapies decreased resistive pressure, probably due to an increase in the internal diameter of the central airways and a reduction in collagen fiber content in the distal airways. BMMC therapy led to a more pronounced reduction in viscoelastic pressure and static elastance than MSC administration, a finding that may be associated with explain less alveolar collapse and reduction in collagen deposition in the alveolar septa in the OVA-BMMC group. These results corroborate the findings of a previous study that evaluated the role of BMMC therapy using the same experimental protocol (Abreu et al., 2011) . Therefore, the fact that the reduction in these histological changes was more pronounced with BMMC therapy may be associated with greater improvement in lung mechanics.
The clinical implication of these findings is associated with the advantages of using BMMCs over MSCs, namely the fact that BMMCs may be used in autologous transplantation (thus avoiding potential cell rejection) and on the same day of harvesting.
This study has some limitations. First, saline was administrated rather than fibroblasts, since fibroblasts have been shown to yield no beneficial effects (Xu et al., 2007) . Furthermore, it is speculated that MSCs constitute a unique cell type, distinct from fibroblasts (Martinez et al., 2007) . Second, other cytokines and growth factors in addition to those analyzed in this study may be involved in the airway remodeling process. Third, even though the number of animals in each group was relatively small (n = 6), three sets of experiments were conducted to assess reproducibility and reliability. Finally, BMMCs are a heterogeneous mix that includes hematopoietic cells, a variety of inflammatory cell types, and a small number of cells with phenotypic characteristics of MSCs. Preclinical models have demonstrated that the hematopoietic fraction could differentiate into lineages that could regenerate damaged tissue (Lakshmipathy and Verfaillie, 2005) , whereas MSCs have immunomodulatory properties and release trophic factors, accelerating the repair process and regenerating viable tissue, thereby improving lung function (Ou-Yang et al., 2011) . The present study was unable to evaluate which combination of cells observed in the BMMC pool yielded better effects. Further studies are warranted to evaluate additional mechanisms of action of BMMCs and MSCs, as well as the potential role of the combination of different cell types found in BMMCs.
In conclusion, in the murine model of allergic asthma used herein, both BMMC and MSC administration were effective in reducing airway inflammation and remodeling and improving lung function. However, the improvement in lung mechanics and histology was more evident after BMMC administration, suggesting that the interaction between the multiple cell types present in the bone marrow mononuclear fraction plays an important role in these processes. These observations have several implications for the framework of future clinical studies, due to the aforementioned advantages of BMMCs over MSCs.
